Effect of SIMBRINZA™ As an Added Therapy to a Prostaglandin Analogue

This study is divided into 2 sequential phases. The Screening/Eligibility phase includes one
screening visit and two eligibility visits, during which subjects will washout of all other
IOP-lowering medications and dose with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled
in each eye once daily for 28 days. Subjects who meet all inclusion/exclusion criteria will
be randomized at the second eligibility visit. The Treatment phase consists of two
on-therapy visits (Week 2 and Week 6).

Inclusion Criteria:

- Diagnosis of open angle glaucoma (including open-angle glaucoma with
pseudoexfoliation or pigment dispersion) or ocular hypertension;

- Mean intraocular pressure (IOP) measurements in at least 1 eye (study eye) of ≥ 21
mmHg and <32 mmHg at 2 consecutive visits (Eligibility 1 and Eligibility 2);

- Able to understand and sign Informed Consent Document;

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Women of childbearing potential who are pregnant, breastfeeding, or do not agree to
use an adequate birth control method throughout the study;

- Any form of glaucoma other than open angle glaucoma or ocular hypertension;

- Severe central visual field loss;

- Chronic, recurrent, or severe inflammatory eye disease;

- Ocular trauma within the past 6 months;

- Ocular infection or ocular inflammation within the past 3 months;

- Best-corrected visual acuity score worse than approximately 20/80 Snellen;

- Eye surgery within the past 6 months;

- Any condition, including severe illness, which would make the subject unsuitable for
the study in the opinion of the Investigator;

- Use of any additional topical or systemic ocular hypertensive medication during the
study;

- Patients who, in the opinion of the Investigator, cannot discontinue all IOP-lowering
ocular medication(s) per the appropriate washout schedule prior to Eligibility 1
Visit;

- Other protocol-defined exclusion criteria may apply.